Ketamine and Midazolam Infusions for CRPS: Feasibility Study

• Status: Withdrawn
• Trial end date: 2024-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Ketamine; Midazolam

Criteria

• Age 18 to 65 years

• Meets the International Association for the Study of Pain (IASP) diagnostic criteria for complex regional pain syndrome (CRPS)

• Primary complaint of CRPS-attributable pain for ≥3 months

• Average pain intensity of ≥3/10 over the last month

• Can read and comprehend English-language questionnaires

• Can receive text messages by phone

• Can identify a responsible adult who can provide transportation to and from infusion site for 5 consecutive days (Mon-Fri)